Title of retracted article: The Results Observation on Adjuvant Chemotherapy with Microwave
Hyperthermia and Stereotactic Radiotherapy in Retreated Elderly Patients with Advanced (III/IV Stage)
Author(s): Xihao Yu1, Xinping Li1, Guiyun Dong1, Wenyan Yu2, Jianping Wang1, Ying Xiong
DOI (to PDF):
* Corresponding author. Email:firstname.lastname@example.org
Journal: Journal of Computer and Communications(JCC)
Pages (from - to): 79 - 82
Paper ID at SCIRP: 64147
Article page: http://www.scirp.org/Journal/PaperInformation.aspx?PaperID=64147
Retraction date: 2016-03-21
Retraction initiative (multiple responses allowed; mark with X):
Some of the authors:
Editor with hints from Journal owner (publisher)
Date initiative is launched: 2016-03-21
Retraction type (multiple responses allowed):
Lab error Inconsistent data Analytical error Biased interpretation
Failure to disclose a major competing interest likely to influence interpretations or recommendations
Data fabrication Fake publication Other:
Plagiarism Self plagiarism Overlap Redundant publication *
Copyright infringement Other legal concern:
Handling error Unreliable review(s) Decision error Other:
Publish in inappropriate journal
Results of publication (only one response allowed):
are still valid.
were found to be overall invalid.
Author's conduct (only one response allowed):
none (not applicable in this case – e.g. in case of editorial reasons)
* Also called duplicate or repetitive publication. Definition: "Publishing or attempting to publish substantially the same
work more than once."
Expression of Concern:
yes, date: yyyy-mm-dd
yes, date: yyyy-mm-dd
Free style text with summary of information from above and more details that can not be
expressed by ticking boxes.
This article has been retracted to straighten the academic record. In making this decision the Editorial Board
follows COPE's Retraction Guidelines. Aim is to promote the circulation of scientific research by offering an ideal
research publication platform with due consideration of internationally accepted standards on publication ethics. The
Editorial Board would like to extend its sincere apologies for any inconvenience this retraction may have caused.
Editor guiding this retraction: Firstname Lastname
(function e.g. EiC, journal abbreviation)
Instructions for Further Editorial Changes to the Online Publication (to be deleted from final notice)
• On the article page ...
o ... the title is preceded by the te xt :
o ... the abstract is exchanged by ...
... a heading: Short Retraction Notice
... body text: The comment from above
... a final text: The full retraction notice in PDF is preceding the original paper,
which is marked "RETRACTED".
o ... the reference under the heading Cite this paper is deleted.
o ... the metadata in the HTML source code of the article page is only changed with respect to the abstract:
<meta name="description" content="..." /> and <meta name="citation_abstract" content="..." /> and
<meta name="dc.description" content="..." />
are set to the same new abstract as explained above and consist of:
the heading, the body text, a final text (without the link).
• The original article in PDF...
o ... receives on each page a red watermark RETRACTED (running diagonally across each page in big letters),
o ... is preceded with the Retraction Notice from these two pages (but without these i ns t ruc t i o ns ), which is showing on
top the CrossMark logo with the link * set to the publication date of the retraction,
o ... gets the link * under the CrossMark logo of the original article changed to the publication date of the retraction,
• The original article in HTML ...
o ... is replaced by the Short Retraction Notice copied from the article page.
o ... has a final text: Please see the article page for more details.
The full retraction notice in PDF is preceding the original paper, which is marked "RETRACTED".
o ... the metadata in the HTML source code is changed as explained above.
• The XML of the original article is deleted.
* The link under the CrossMark logo follows the pattern:
yyyy-mm-dd is the date (ISO 8601).
Journal of Computer and Communications, 2016, 4, 79-82
Published Online Ma rch 2016 in SciRes. http://www.scirp.org/journal/jcc
How to cite this paper: Yu , X.H., et al. (2016) The Results Observation on Adjuvant Chemotherapy with Microwave Hyper-
thermia and Stereotactic Radiotherapy in Retreated Elderly Patients with Advanced (III/IV Stage) Lung Cancer. Journal of
Computer and Communications, 4, 79-82. http://dx.doi.org/10.4236/jcc.2016.43012
The Results Observation on Adjuvant
Chemotherapy with Microwave
Hyperthermia and Stereotactic
Radiotherapy in Retreated Elderly
Patients with Advanced
(III/IV Stage) Lung Cancer
Xihao Yu1, Xinping Li1, Guiyun Dong1, Wenyan Yu2, Jianping Wang1, Ying Xiong1
1Department of Oncology of Liberation Army 85 Hospital, Shanghai, China
2Basic Medical College of Shanghai Jiaotong University, Shanghai, China
Received 14 January 2016; accepted 26 February 2016; published 2 March 2016
Objective: To evaluate the significance of adjuvant chemotherapy and radiotherapy (Gamma-knife)
in the elderly patients with retreated advance lung cancer. Methods 83 patients (age 50 to 81
years) with retreating advanced (III/IV stage) lung cancer were divided into three groups accord-
ing to patients received treating by different methods. The cases were treated by synchronous
chemo-radiotherapy (A group), sequentially chemo-radiotherapy (B group) and continuous sys-
tematized chemotherapy alone (C group). The systemic 3-dimensional orientation apparatus was
used in radiotherapy. The chemotherapy regimen in combined radiotherapy was given by com-
mon first line regimen on lung cancer. The regimen of chemotherapy combated with whole body
hyperthermia by using micro-wave on abodeman about 2 or 3 line was used in C group only. Re-
sults: The overall responses rates (RR) of A, B and C groups were 17.1%, 11.5% and 31.8%, but it
was non-significance difference (P > 0.05). Overall responses rates (RR) of III and IV stage groups
were 18.2% and 20.0%. The average overall survival time (OS) and median survival time (MST) of
the patients treated by chemotherapy (C group) were highest about 14.2 and 9.3 months (respec-
tively at A group 6.7 and 6.0 months. P < 0.01), in which B group was longer than A group (P <
0.05), and 95.5% CI value was not overlap. The total survival time of postoperative patients was
longer in the various groups by different treated than that in non-operations. Conclusion: The
rates (RR) of III and IV stage groups were non-significance difference. The higher of ORR, OS and
MST in a few patients of re-treated advanced lung cancer was presented in case with treated by
continuous system chemotherapy. There were survival superiority in initial postoperative pa-
tients groups by different treated. It is a profitable and effect treatment that the pure reasonable
systemic chemotherapy was used for elderly case with advanced retreated lung cancer.
X. H. Yu et al.
Elderly Patients, Chemotherapy, Combined Radiotherapy, Lung Cancer
The retreating to elder patients with advanced lung cancer is a problems that often needs to be faced in clinical
practice. A number of studies have shown that appropriately chemotherapy or radiotherapy is better than the best
supportive care. Due to the special physiological function of old patients, it was considered that how to choose
the best treatment for the patients. Especially for patients treated again, at present this kind of research is not
much. It is object about the paper to investigate the effect and significance of adjuvant chemotherapy with
hyperthermia and radiotherapy (Gamma-knife) in the treatment of elderly patients with retreated advance lung
2. Clinical Material and Methods
Eighty-three patients, median age 67.3 year (50 to 81 years), with retreating advanced (III/IV stage) lung cancer
were divided into three groups according to patients received treating by different methods. 35 cases were
treated by synchronous chemo-radiotherapy (group A). 26 cases were treated by sequentially chemo-radiothe-
rapy (group B) and 22 cases were treated by continuous systematized chemotherapy alone (group C). (see Table
1). All patients were selected for inclusion in study after the initial treatment stoped 2 - 3 months. The systemic
3-dimensional orientation apparatus was used in radiotherapy. The total dose of 35-55GY was given in syn-
chronous or sequential chemo-radiotherapy. The chemotherapy regimen in combined radiotherapy was given by
common first line regimen on lung cancer. (NSCLC: NVB25 mg/m2 d1, 8, GEM 0 .8 - 1.0/m2 d1, 8, DDP 40 mg
d1-3 or D DP 20 mg d1-5. SCLC: CBP AUC = 5, VP16 0.1/m2. q21d). The part chemotherapy combated with
whole body hyperthermia by using micr o-wave on abodeman in temperature 40˚C - 42˚C for 1 - 2 hours. The
regimen of chemotherapy about 2 or 3 line was used in C group only. Drugs was used at Taxol (Squibb US, Co)
175 mg/ m2 d1, or Docertacel (Aventis Pharma, SA, Co) 70 - 80 mg/m2, d1; Pemetrexed (Lilly France SAS, Co)
500 mg/m2, d1.). The responce rate was statistically based on RECIST (WHO) method.
Statistical analysis The categorical variables percent date were compared between the two groups by using the
inpendent X2 test. Continuous data were compared between two groups by using independent t test. A two-tailed
P value of < 0.05 was considered statistically significant. Survival was calculated by using the Kaplan-Meier
method and compared by using the log-rank test. The Kaplan-meier curve was used to exhibit survival time.
1) The overall responses rates (RR) of A, B and C groups were 17.1%, 11.5% and 31.8%, but it was non-sig-
nificance difference respectively at three group (P > 0.05). The higher effective rate was presented in stage III
case with synchronous chemo-radiotherapy (23.1%), and in stage IV with continuous systematized chemothera-
py alone (38.5%), but overall responses rates (RR) of III/IV stage groups was non-significance difference (18.2%
and 20.0%) (see Table 2).
2) The average overall survival time (OS) and median survival time (MST) of the patients treated by chemo-
Table 1. The general state of the patients with cancer on different treating groups.
Groups Cases SEX Mid-age Stage (%) PS (%)
M F III IV ≤2 ≥3
group A 35 23 12 54.6 13 (37.1) 22 (62.8)* 25 (71.4) 10 (28.6*)
group B 26 20 6 51.2 11 (42.3) 15 (57.7) 16 (61.5) 10 (38.5)
group C 22 13 9 56.5 9 (40.9) 14 (63.7)* 14 (63.7) 8 (36.3)
*P > 0.05.
X. H. Yu et al.
therapy (C group) were highest about 14.2 and 9.3 months (respectively at A group 6.7 and 6.0 months. P <
0.01), in which B group was longer than A group (P < 0.05), and 95.5% CI value was not overlap. The Kap-
lan-meier curve for survival time was showed (shown in Figu re 1).
3) The total survival time of initial postoperative patients were longer in the various groups by different
treated than that in non-operations (see Table 3).
Table 2. The contrast about respond rate (RR) in different treating groups.
Group Stage III Stage IV RR (%)
N RR (%) N RR (%)
Syn.che-rad (A) 13 3 (23.1) 22 3 (13.6)# 6/35 (17.1)
Seq.che-rad (B) 11 1 (9.1) 15 2 (13.3) 3/26 (11.5)
Chem.onl (C) 9 2 (22.2) 13 5 (38.5)+ 7/22 (31.8)*
33 6 (18.2) 50 10 (20.0) 16/83 (19.3)
*X2 = 1.87. P > 0.05 (contrast between C and B); +X2 = 2.86. P > 0.05 (contrast between C and A); #X2 = 0.51 P > 0.05 (contrast between stage IV and
III in A group).
Table 3. Survival time (months) on different treating groups with post-operation.
Content No operation Post-operation
Syn.che-rad (A) 30 6.5 5.0 5 19.2 13.4
Seq.che-rad (B) 20 9.9 7.0 6 17.0 15.0
Chem.onl © 17 10.9 9.0 5 25.2 15.0
65 9.1 7.0 16 20.5 14.5*
*t = 2.79. P < 0.01 (post-ope.cont no ope. about MST).
Figure 1. The Kaplan-meier survival rate of different treating groups. 一●: group A, 一■: group B, 一▲:group C.
X. H. Yu et al.
Stereotactic gamma knife radiotherapy for intracranial tumor and somatic localized tumors can make small part
of radical effect to the operation as a knife. However, chemotherapy is often needed for patient with recurrence
and metastasis . However studies have indicated that, after radiotherapy or early chemotherapy, the residual
tumorcells can accelerate the proliferation, which make the tumor more difficult to control . So it is very im-
portant to follow up the system chemotherapy or consolidation chemotherapy. Hyperthermia can increase the ef-
ficacy of chemotherapy and reduce side effect, in which it can appropriately reduce the dose of chemotherapy
drug and more suitable for the elderly. Although surgical treatment of lung cancer, especially in the initial
treatment still occupies an important position , our research also shows that there were survival superiority in
initial postoperative patients groups by subsequent different treated. But it is not possible for the elderly tumor
patients to choose again. This clinical observation study of this paper suggested that the synchronous chemo-
radiotherapy can partly increased about RR of the patients with stage I II case, and higher effective rate was pre-
sented in stage IV with continuous systematized chemotherapy, but the rates (RR) of III and IV stage groups
were non-significance difference. The higher of ORR, OS and MST in a few patients of re-treated advanced
lung cancer was presented in case with treated by continuous system chemotherapy. Conclusion: It is a profita-
ble and effect treatment that the pure reasonable systemic chemotherapy was used for elderly case with ad-
vanced retreated lung cancer.
 Lin, J.-C., Jan , J.-S., Hsu, C.-Y., et al. (2003) Phase 3 Study of Concurrent Chemoradiotherapy versus Radiotherapy
Alone for Advanced Nasopharyngeal Carcinoma: Positive Effect on Overall and Progression-Free Survival. Journal of
Clinical O ncolog y, 21, 631-637. http://dx.doi.org/10.1200/JCO.2003.06.158
 Mehta, M., Scrimger, R., Mackkie, R., et al. (2001) A New Approach to Dose Escalation in Non-Small-Cell Lung
Cancer. International Journal of Radiation Oncology Bio logy Physics, 49, 23-33.
 Nagai, K., Sohara, Y., Tsachiya, R., et al. (2007) Prognosis of Resectd Non-Small Cell Lung Cancer Patients with
Intrapalmonary Metastases. Journal of Thoracic Oncology, 2, 282-286.